Nuclear magnetic resonance

Nanalysis Enters into a Letter of Intent to Acquire Quad Systems AG

Retrieved on: 
Tuesday, January 18, 2022
Forward-looking statement, Working capital, IP, Technology, News, Intention, GAAP, EBITDA, Agrochemical, Miniaturization, Nuclear magnetic resonance, Board of directors, IFRS, Stock, Partnership, Equity, Mining, CEO, NMR, OTCQX, Government, Bruker, OEM, OTC, Industry, Law enforcement, Company, Corporation, CHF, TSX Venture Exchange, Doctor of Philosophy, MRI, ETH Zurich, Multimedia, Letter, NSCI, Mission statement, LOI, Organization, Board, Medical imaging, Fine chemical, Security (finance), Bank, Nanalysis, Physics

CALGARY, Alberta, Jan. 18, 2022 /PRNewswire/ - Nanalysis Scientific Corp. ( TSXV:NSCI ,OTCQX:NSCIF,FRA:1N1) ("Nanalysis" or the "Company") ispleased to announce that it has entered into a letter of intent to acquire QUAD Systems AG (Quad Systems), a Zurich-based Nuclear Magnetic Resonance (NMR) company focused on high-field NMR for pharmaceutical and other vertical markets.

Key Points: 
  • CALGARY, Alberta, Jan. 18, 2022 /PRNewswire/ - Nanalysis Scientific Corp. ( TSXV:NSCI ,OTCQX:NSCIF,FRA:1N1) ("Nanalysis" or the "Company") ispleased to announce that it has entered into a letter of intent to acquire QUAD Systems AG (Quad Systems), a Zurich-based Nuclear Magnetic Resonance (NMR) company focused on high-field NMR for pharmaceutical and other vertical markets.
  • Therefore, in addition to converting our OEM relationship with Quad Systems to a closer partnership, there are also tremendous cross-selling opportunities.
  • As part of the agreement, Nanalysis has provided Quad Systems with a CHF 1,000,000 loan (Loan) which is convertible into shares in the capital of Quad Systems, and Sean Krakiwsky, founder and CEO of Nanalysis is being appointed to Quad Systems' Board of Directors as a Nanalysis nominee immediately.
  • On completion of the Equity Investment a second representative of Nanalysis will be appointed to Quad Systems' Board of Directors.

Nanalysis Announces the Closing of Acquisition of K'(Prime) Technologies Inc.

Retrieved on: 
Wednesday, January 12, 2022
Forward-looking statement, Daou Technology Inc., News, Intention, FRA, Agrochemical, Nuclear magnetic resonance, Mining, NMR, Government, Nanalysis, AB, OTC, Industry, Law enforcement, Company, Food, Corporation, TSX Venture Exchange, MRI, Multimedia, NSCI, Acquisition

Sean Krakiwsky, Chief Executive Officer of Nanalysis stated, "We are thrilled to make KPrime part of the Nanalysis corporate family and look forward to integrating the best of our two operations and driving sales of Nanalysis' various product lines.

Key Points: 
  • Sean Krakiwsky, Chief Executive Officer of Nanalysis stated, "We are thrilled to make KPrime part of the Nanalysis corporate family and look forward to integrating the best of our two operations and driving sales of Nanalysis' various product lines.
  • We will always be a product innovation company, with customer service as a critical part of our business."
  • Nanalysis trades on the TSX Venture Exchange (TSXV) in Canada with ticker symbol 'NSCI', OTC and the Frankfurt exchange under the ticker symbol '1N1'.
  • The company develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets.

Nanalysis Appoints Dr. René Lenggenhager to Board of Directors

Retrieved on: 
Wednesday, December 15, 2021
Nuclear magnetic resonance, Forward-looking statement, University of St. Gallen, Law enforcement, Board of directors, OTC, Government, Physics, Company, ETH Zurich, Board, Doctor of Philosophy, MTD, Mettler Toledo, Automation, Growth, OTCQX, Industry, Agrochemical, Intention, CEO, Marketing, Comet Group, NMR, CovalX, NSCI, Offering, Indian stock exchange, Federal Institute of Science and Technology, AB, TSX Venture Exchange, Siemens Building Technologies, Multimedia, Legislation, University, Mining, Corporation, MRI, COTN, News, Technology, Security (finance), Management, Nanalysis

CALGARY, AB, Dec. 15, 2021 /PRNewswire/ - Nanalysis Scientific Corp. ("Nanalysis" or the "Company"), TSXV:NSCI , OTCQX:NSCIF, FRA:1N1) ispleased to announce that, effective January 1, 2022, Dr. Ren Lenggenhager, is joining its Board of Directors.

Key Points: 
  • CALGARY, AB, Dec. 15, 2021 /PRNewswire/ - Nanalysis Scientific Corp. ("Nanalysis" or the "Company"), TSXV:NSCI , OTCQX:NSCIF, FRA:1N1) ispleased to announce that, effective January 1, 2022, Dr. Ren Lenggenhager, is joining its Board of Directors.
  • Dr. Lenggenhager is an experienced public company executive and board member with a successful career in leading global technology companies.
  • Dr. Ren Lenggenhager states, "I am enthusiastic about joining the Nanalysis team, at the Board level, and helping management continue to refine and focus its product strategy.
  • Chair of the Board of Directors, Mr. Martin Burian adds, "We welcome Ren to the Nanalysis Board of Directors, and look forward to working with him particularly in the context of our strategic evolution and growth.

INRS receives more than $1.5 million for its collaboration in the project Le Consortium Acuité-Qc

Retrieved on: 
Monday, December 13, 2021
Nuclear magnetic resonance, Varennes-en-Argonne, Artificial intelligence, Workforce Innovation in Regional Economic Development, Cancer, FACS, Center, DEL, Economic development, Student, MONTRAL, Innovation, Institute, Research, Mila (research institute), Universitate metro station, Machine learning, Biophysics, Pharmacology, INRS, Investment, Consortium, Pharmacy, Agreement Respecting a New Relationship Between the Cree Nation and the Government of Quebec, Technology, Ministry of Economy and Innovation (Lithuania), Drug development, Interdisciplinarity, Sherbrooke, Drug discovery, Pharmaceutical industry, Medical imaging

MONTRAL and LAVAL, Dec. 13, 2021 /CNW Telbec/ -The Institut national de la recherche scientifique (INRS) has been awarded $1.5 million for its collaboration in the project "Le Consortium Acuit-Qc: prdire et visualiser l'action du medicament".

Key Points: 
  • MONTRAL and LAVAL, Dec. 13, 2021 /CNW Telbec/ -The Institut national de la recherche scientifique (INRS) has been awarded $1.5 million for its collaboration in the project "Le Consortium Acuit-Qc: prdire et visualiser l'action du medicament".
  • This large-scale project involves INRS Professor Steven Laplante as a co-applicant; he is an expert in the discovery of therapeutic molecules and tools to study their properties.
  • He will contribute to the early integration of advanced biophysical techniques to guide the design of molecular databases called chemical libraries.
  • They account for investments of more than $74 million over three years, including $35 million in government support.

Ionis' antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021

Retrieved on: 
Friday, November 12, 2021
Amyloidosis, AHA, Oral, COVID-19, Treatment, Science, Association, Annual report, Nuclear magnetic resonance, Therapy, Diagnosis, Atheroma, African Americans, Hypertriglyceridemia, Prevalence, Risk, CORE, Safety, Plasma, Form 10-K, PCSK9, Blood, Learning, Research, Emory University, Biotechnology, Stanford University, Columbia University, Cardiomyopathy, Patient, LICA, View, FAT, Heart, NASDAQ, Knowledge, Liver, Goal, Multimedia, Heart failure with preserved ejection fraction, Dyslipidemia, Moyamoya disease, Pharmacokinetics, IONS, AstraZeneca, Lipoprotein, RNA, NMR, Virginia Commonwealth University, Cardiovascular disease, Judgement, Lipoprotein(a), Company, Heart failure, Committee, Pharmaceutical industry

New data from the Phase 1 multiple ascending dose study for ION449 (also known as AZD8233) will be featured in an oral presentation.

Key Points: 
  • New data from the Phase 1 multiple ascending dose study for ION449 (also known as AZD8233) will be featured in an oral presentation.
  • ION449 is being developed by AstraZeneca as part of a collaboration between Ionis and AstraZeneca.
  • The apolipoprotein C-III (apoC-III) protein is an independent cardiovascular risk factor that regulates triglyceride metabolism in the blood.
  • Transthyretinamyloid cardiomyopathy, or ATTR-CM, is a serious and underdiagnosed type of amyloidosis that primarily affects the heart and leads to heart failure.

numares and Oxford University sign exclusive license agreement for novel multi-marker diagnostics in multiple sclerosis

Retrieved on: 
Thursday, October 28, 2021
Technology, Medical Devices, Finance, Venture Capital, Professional Services, Biotechnology, Hardware, Health, Pharmaceutical, Nuclear magnetic resonance, Research, Diagnosis, CVD, University, Disease, Glomerular filtration rate, Partnership, RRMS, Software, Patient, Adoption, Multiple sclerosis, Machine learning, Cardiovascular disease, SPMS, HIV disease progression rates, Food, AG, Department of Pharmacology, University College London, MS, Risk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GFR, CEO, Biomarker, Oxford University Innovation, Multimedia, Alzheimer's disease, IVD, University of Oxford, Health, Sale, Department, Physician, NMR, Medical imaging, Pharmaceutical industry

Leading NMR diagnostics company numares AG today announced that the company signed an exclusive licence agreement with Oxford University Innovation.

Key Points: 
  • Leading NMR diagnostics company numares AG today announced that the company signed an exclusive licence agreement with Oxford University Innovation.
  • This allows numares to translate and exploit preliminary work of Oxford University on Multiple Sclerosis (MS) biomarkers for the development of an urgently needed in-vitro diagnostics (IVD) test able to detect disease progression earlier to improve patient management and outcome.
  • The exclusive licence enables numares to further develop the biomarkers into a multi-marker based diagnostic test and commercialization thereof.
  • Most patients with "relapsing remitting multiple sclerosis (RRMS)" will eventually transition to "secondary progressive multiple sclerosis (SPMS)" with continuous worsening of symptoms.

Azzur Labs Strengthens National Foothold with New Leadership and Testing Capabilities in Chicago and Raleigh

Retrieved on: 
Monday, August 2, 2021

Cecil Runyon brings to Azzur Labs more than 17 years of experience and will oversee all operations and client relations for the Chicago operation.

Key Points: 
  • Cecil Runyon brings to Azzur Labs more than 17 years of experience and will oversee all operations and client relations for the Chicago operation.
  • Prior to joining Azzur Labs, Cecil spent several years in the pharmaceutical, medical device, and cosmetic industries.
  • Jorge brings to Azzur Labs Raleigh more than 15 years of experience in cell and molecular biology.
  • "Azzur Labs is excited to welcome both Cecil and Jorge as leaders on our team," said Kym Faylor , President of Azzur Labs.

New Alliance will Deliver Added Value to the NHP Industry

Retrieved on: 
Thursday, July 8, 2021
Toyota iQ, ISO/IEC 17025, Nuclear magnetic resonance, Intelligence quotient, Probiotic, Motor vehicles, Transport, Academic disciplines

AFL is accredited by the Standards Council of Canada through U of G's Laboratory Services Division.

Key Points: 
  • AFL is accredited by the Standards Council of Canada through U of G's Laboratory Services Division.
  • Purity-IQ aims to deliver innovative genomic (DNA) and metabolomic (NMR) analytical tools for industry to cost-effectively identify and authenticate products for consumers, protect biodiversity and ensure the sustainability of raw NHP ingredients.
  • "Adding AFL as a commercial ISO 17025 lab service rounds out our Purity-IQ commercial offerings and allows us to expand our existing probiotic species identity and authenticity services to the NHP industry.
  • "The collective expertise and experience amongPurity-IQ, the NHPRA and theAFL allows us to bring new methods online quickly to support the NHP industry."

Hprobe Announces Breakthrough in High-Volume Testing for Automotive/Consumer Advanced 3D Magnetic Sensors

Retrieved on: 
Tuesday, June 15, 2021
Other Manufacturing, Technology, Semiconductor, Automotive, Other Technology, Automotive Manufacturing, Professional services, Other Automotive, Manufacturing, Other Professional Services, Electromagnetism, Magnetism, Measuring instruments, Magnetometer, Nuclear magnetic resonance, Sensors, Magnetic field, Automatic test equipment, Magnet

Hprobe, a provider of semiconductor Automated Test Equipment (ATE) for magnetic devices, today announced the demonstration of a new 3D magnetic generator design resulting in magnetic field accuracy of less than 5T (5 microteslas) for wafer level probing of 3D angular magnetic sensors.

Key Points: 
  • Hprobe, a provider of semiconductor Automated Test Equipment (ATE) for magnetic devices, today announced the demonstration of a new 3D magnetic generator design resulting in magnetic field accuracy of less than 5T (5 microteslas) for wafer level probing of 3D angular magnetic sensors.
  • Operating with automated wafer probing stations and external electrical testers, this major breakthrough offers significant throughput performance for testing advanced 3D magnetometers.
  • It is the latest evolution in Hprobes unique patented 3D magnetic field generator technology for single and multi-site testing at wafer level, under a magnetic field.
  • Hprobes new 3D magnetic generator design can be integrated into the companys existing equipment, which consists of a test head with a robotized 3D magnetic generator.

Nano Dimension Reports 2021 First Quarter Financial Results with CEO Letter to Shareholders

Retrieved on: 
Thursday, May 20, 2021
Software, Computing, Free software, Cryptocurrencies, Nano, XC2, Nuclear magnetic resonance, Printed electronics, NASDAQ, GNU nano

b'SUNRISE, Fla., May 20, 2021 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM), a leading Additively Manufactured Electronics (AME)/PE (Printed Electronics) provider, today announced financial results for the first quarter ended March 31, 2021.\nNano Dimension reported revenues of $811,000 for the first quarter of 2021.

Key Points: 
  • b'SUNRISE, Fla., May 20, 2021 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM), a leading Additively Manufactured Electronics (AME)/PE (Printed Electronics) provider, today announced financial results for the first quarter ended March 31, 2021.\nNano Dimension reported revenues of $811,000 for the first quarter of 2021.
  • The Company ended the quarter with a cash and deposits balance of $1,471,014,000 (including short and long-term unrestricted bank deposits), while net loss for the first quarter was $9,314,000.\nMr.
  • In fact, we just announced the sale of a DragonFly LDM\xc2\xae to the University of Quebec in Canada.
  • Nano Dimension is not responsible for the contents of third party websites.\n'